Oppenheimer Asset Management Inc. Invests $904,000 in Henry Schein, Inc. (NASDAQ:HSIC)

Oppenheimer Asset Management Inc. bought a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 13,067 shares of the company’s stock, valued at approximately $904,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc raised its position in shares of Henry Schein by 274.6% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $32,000 after acquiring an additional 335 shares in the last quarter. Venturi Wealth Management LLC raised its position in shares of Henry Schein by 3,347.1% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock worth $41,000 after acquiring an additional 569 shares in the last quarter. Quent Capital LLC raised its position in shares of Henry Schein by 91.2% during the 4th quarter. Quent Capital LLC now owns 677 shares of the company’s stock worth $47,000 after acquiring an additional 323 shares in the last quarter. City State Bank purchased a new position in Henry Schein during the 4th quarter worth approximately $55,000. Finally, Farther Finance Advisors LLC grew its stake in Henry Schein by 58.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 933 shares of the company’s stock worth $68,000 after buying an additional 346 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Trading Down 0.7 %

Shares of HSIC stock opened at $70.31 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average is $74.41 and its two-hundred day moving average is $72.51. The company has a market capitalization of $8.73 billion, a P/E ratio of 28.93, a price-to-earnings-growth ratio of 2.13 and a beta of 0.91. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.49.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.66 earnings per share. Equities analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analyst Weigh In

HSIC has been the topic of a number of research reports. Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and raised their price target for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. Mizuho initiated coverage on Henry Schein in a research note on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price target on the stock. Barrington Research restated an “outperform” rating and set a $90.00 price target on shares of Henry Schein in a research note on Wednesday, February 26th. UBS Group dropped their price target on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 26th. Finally, StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.